For most of the past decade, PeptideSciences was the default name in research peptide procurement. The site was thorough, the chemistry pages were dense and accurate, and the reputation in research forums was steady. When PeptideSciences wound down operations in late 2025, an entire layer of the research-supply ecosystem dropped out overnight — and a thousand procurement workflows had to find a new home.
This is an honest look at where research labs and independent investigators are looking now: what the alternatives actually offer, what they don’t, and how to evaluate them against the standards the older suppliers set.
What PeptideSciences set as the bar
Before talking about replacements, it’s worth being specific about what was good. PeptideSciences combined three things that newer entrants need to match:
- Independent batch testing — every batch carried an HPLC report from an external lab, not the manufacturer’s own QC.
- Long descriptive pages — molecular formula, CAS, references to the underlying research literature, and a clear “research use only” framing throughout.
- Predictable fulfillment — orders shipped from a known facility, on a known cadence, with replacement policies for delivery failures.
Any alternative worth considering has to match all three, not just one. A supplier with great chemistry pages but no third-party testing isn’t actually equivalent. A supplier with good testing but unpredictable shipping is operationally untenable for serial research procurement.
How the post-shutdown landscape sorted itself out
Within a few months of PeptideSciences exiting, the remaining suppliers fell roughly into four buckets:
Bucket 1 — Established US-only suppliers with thin transparency
Several long-standing US vendors picked up volume. Reputation is generally solid, but most do not publish independent COAs by default; you have to request them, and the COA may or may not arrive. Pricing tends to be 20-40% higher than what PeptideSciences charged for equivalent vials. These vendors are appropriate for researchers who already have a relationship and aren’t price-sensitive.
Bucket 2 — High-volume aggregators
A second cluster focuses on volume over verification. Pricing is aggressive, but third-party COAs are inconsistent and the underlying batch source can change quarterly. These vendors are usable for cheap exploratory work where the cost of a bad batch is low, but not appropriate where research reproducibility matters.
Bucket 3 — Canadian-friendly small shops
Cross-border fulfillment is the operational hardest part of research peptide procurement, and the suppliers that ship cleanly into Canada are valuable disproportionate to their size. These are the smaller players — sometimes single-operator — that publish reship policies, accept crypto, and have learned how to package and route shipments through Canadian customs. The trade-off is catalog depth: most carry 20-40 compounds, not 100+.
Bucket 4 — New entrants with the testing bar
A handful of new entrants since late 2025 are explicitly trying to fill the PeptideSciences-shaped gap: third-party tested every batch, descriptive product pages, US + Canada fulfillment, predictable replacements. This is the cluster where most of the procurement migration has gone.
What to look for when evaluating an alternative
Three concrete things to check before committing to a recurring procurement relationship:
1. Independent COAs, published per batch, not on request
The Janoshik Analytical (janoshik.com) lab in Czechia is currently the most-trusted third-party testing house in the research peptide space — HPLC for purity, LC-MS for identity and mass accuracy, and reports are timestamped and verifiable. A supplier publishing Janoshik reports against the specific batch you’re buying is a fundamentally different trust level than a supplier publishing a single representative COA from months ago.
The minimum bar: ask any prospective supplier for the COA of the exact batch you’d receive, before you order. If they can’t produce it, they’re not actually third-party tested per batch.
2. Reconstitution and storage guidance, accurately stated
Reconstitution math is not difficult, but it’s frequently wrong on supplier pages. A supplier that publishes a thoughtful reconstitution calculator or worked-example math (peptide mg ÷ bacteriostatic water mL × volume drawn = mg delivered) is signaling something about operational seriousness that a supplier saying “ask your researcher” is not.
Storage guidance for lyophilized vs reconstituted material matters too: lyophilized peptides are generally stable at room temperature for weeks; reconstituted peptides need 2-8°C storage and have variable shelf lives by compound.
3. Shipping policy that anticipates customs
Customs interception is a reality of cross-border research procurement. Roughly 10% of US-to-Canada shipments of any pharmaceutical-class material can be held at the border. The supplier’s policy on intercepted shipments is the single largest determinant of whether the relationship works long-term: do they replace at no cost, do they require evidence, do they require waiting before re-shipping?
A supplier with a clean “free reship if customs seizes” policy is taking on the operational risk that you would otherwise carry. A supplier that punts the problem back to the customer is, in practice, charging a hidden 10% premium on every Canadian order.
How the four buckets compare
Mapped against the three criteria that actually matter for serial procurement:
| Option type | Independent per-batch COA | US + Canada fulfillment | Free customs reship | Catalog depth |
|---|---|---|---|---|
| Bucket 1 — established US-only | On request only | US-only | Rare | Broad |
| Bucket 2 — high-volume aggregators | Inconsistent | Varies | Rare | Very broad (100+) |
| Bucket 3 — Canadian-friendly small shops | Sometimes | Yes | Often | Narrow (20–40) |
| Bucket 4 — new entrants w/ testing bar (incl. Bastion) | Published per batch | Yes | Yes | Focused (~30) |
The pattern across the market: the suppliers that publish a per-batch COA and solve cross-border fulfillment are rare, which is exactly the gap the PeptideSciences exit left open.
Concrete starting points for re-procurement
For researchers rebuilding their supplier shortlist:
- If you primarily need GLP-1 receptor agonists — Semaglutide and the dual/triple agonists (Tirzepatide, Retatrutide, compared side by side in our GLP-1 research guide) are the most-supplied class in the post-PeptideSciences market. Bundle pricing on these has improved sharply since late 2025.
- If you primarily need soft-tissue research peptides — BPC-157 and TB-500 are widely available; testing quality varies dramatically by supplier. Insist on per-batch HPLC.
- If you primarily need growth-hormone secretagogues — Ipamorelin 5mg (Bastion), CJC-1295, and Sermorelin are the most-supplied class for IGF-1 and pulsatile GH research. These are also the compounds where per-batch identity testing matters most because the mass differences across the family are small.
- If you primarily need longevity / telomere research compounds — Bastion Epithalon 10mg vial and Pinealon are smaller-pool peptides with limited upstream sources; supplier consistency matters more here than for the high-volume metabolic compounds.
- If you need cognitive / neurotrophic compounds — Semax, Selank, and Pinealon are less commoditized and depend on a smaller pool of upstream manufacturers; supplier consistency matters more here than for the high-volume metabolic compounds.
Where Bastion fits
Bastion Peptides is one of the new entrants in Bucket 4. The deliberate positioning: batches tested by Janoshik Analytical via HPLC + LC-MS as verification rolls out across the catalog, Match-Batch COA referenced in the order completion email for verified compounds so you can verify the exact batch you received, free reship on any customs-detained shipment, secure card checkout via PayPal, and US + Canada fulfillment.
The catalog is intentionally narrow — roughly thirty compounds, covering the most-studied research peptides — rather than the hundred-plus aggregator-style listings. That trade-off is deliberate: a narrow catalog with transparent per-SKU verification status is more useful for serial research procurement than a broad catalog where availability is unpredictable — the current verified/pending split for Bastion’s catalog is on the Lab Results page.
If you’re rebuilding a procurement workflow after the PeptideSciences exit, the full catalog page shows everything available, and the Lab Results page shows the Janoshik reports for current batches.
Frequently asked questions
What happened to Peptide Sciences?
PeptideSciences wound down operations in late 2025. The shutdown removed one of the longest-standing default suppliers in research peptide procurement, prompting a broad migration of buyers to newer suppliers that match its standards for per-batch testing and predictable fulfillment.
Is Peptide Sciences coming back?
There is no public indication of a relaunch. Treat the exit as permanent for procurement-planning purposes and evaluate replacements on their own merits — primarily independent per-batch COAs, cross-border fulfillment, and reship policy.
What is the best Peptide Sciences alternative in 2026?
There is no single answer; it depends on your compound mix and whether you need Canadian fulfillment. The strongest replacements are the “new entrants with the testing bar” (Bucket 4) that publish an independent Janoshik COA against the exact batch shipped and reship customs-detained orders at no cost.
How do I verify a Peptide Sciences alternative is legitimate?
Ask for the COA of the exact batch you would receive, before ordering, and confirm it resolves to a real record on the testing lab’s own database. See our Match-Batch verification guide for the 60-second check.
Do any Peptide Sciences alternatives ship to Canada?
Yes. Cross-border fulfillment is the hardest operational piece, so it is a key differentiator. Suppliers with an explicit free-reship policy on customs-detained shipments are taking on the border risk you would otherwise carry. Bastion ships to both the USA and Canada with free reship on seizures.
Are the cheaper aggregator alternatives reliable for research?
For low-stakes exploratory work, sometimes. For reproducible research, inconsistent third-party testing and quarterly-changing batch sources make them risky — a bad batch can invalidate a study. Per-batch independent testing is the dividing line.
What’s next for the research peptide market
Two trends are worth tracking through 2026:
- Per-batch testing as table stakes. The standard PeptideSciences set is now the floor; suppliers without it will increasingly lose serial procurement. Expect more new entrants explicitly marketing Janoshik or equivalent third-party testing.
- Cross-border consolidation. The cost of a successful Canadian fulfillment is going up as carrier policies tighten. Suppliers that solve cross-border cleanly will pull disproportionate share from researchers who need it; suppliers that don’t will become US-only by default.
The PeptideSciences exit was disruptive but not terminal for the ecosystem. The procurement standards it set survive — they’re just spread across more suppliers now, with the bar for “trustworthy” actually higher than before.
For research use only. Bastion Peptides supplies compounds intended for laboratory and in-vitro research. Not for human or veterinary consumption.